KPMG in Ukraine has advised Farmak JSC, a Ukrainian pharmaceutical company, on financial and tax matters in connection with its investment in Symphar, a Polish-based pharmaceutical marketing firm.
KPMG in Ukraine, with involvement of KPMG Poland, performed financial and tax due diligence, analysed financial performance of the company, sustainability of EBITDA, working capital and net debt dynamics as well as significant areas of tax concern that should be addressed within the deal.
Acquisition of Symphar is a part of Farmak’s international expansion strategy to EU markets.
Finance: Svitlana Shcherbatyuk (Project leader), Hanna Butar, Oleksandr Ostrovskyi, Yaroslav Mykuliak
Tax (Poland): Małgorzata Gleń, Anna Kasprzyk, Mariusz Ruta, Agata Głowacka, Oskar Kontny.
Tax (Ukraine): Oksana Olekhova, Mariia Klepakova
About Farmak
Farmak is an international pharmaceutical company, with manufacturing and R&D facilities in Ukraine and Spain, and more than 10 offices globally.
About Symphar
Symphar is a Warsaw-based pharmaceutical company, specializing in the diabetology, gynecology, psychiatry, neurology and other therapeutic areas.
